Abstract
IntroductionTo report on the successes and challenges with implementing the good participatory practice guidelines for the Nigerian Canadian Collaboration on AIDS Vaccine (NICCAV) project.MethodsAn open and close ended questionnaire was administered to 25 randomly selected community stakeholders on the project. The questions sought information on perception about the community entry, constitution and function of the community advisory board (CAB) and community based organization (CBO), media engagement process, and research literacy programmes. The quantitative and qualitative data were analysed and findings triangulated.ResultsThe project exceeded its targets on CBO engagement and community members reached. Stakeholders had significant improvement in knowledge about HIV vaccine research design and implementation (p=0.004). All respondents felt satisfied with the community entry, CAB constitution process, function and level of media engagement; 40% were satisfied with the financial support provided; 70% felt the community awareness and education coverage was satisfactory; and 40% raised concerns about the study site selection with implications for study participants' recruitment.ConclusionThe NICCAV community stakeholder engagement model produced satisfactory outcomes for both researchers and community stakeholders. The inclusion of an advocacy and monitoring plan enabled it to identify important challenges that were of ethical concerns for the study.
Highlights
The field of HIV vaccine development was reinvigorated by the results of the ALVAC-HIV (Sanofi Pasteur)/AIDSVAX B/E (Global Solutions for Infectious Diseases) trial that demonstrated 31.2% protection [1], and lower risk of HIV infection for the study population when compared with populations in other trials [2,3,4,5,6]
We report on the method used for implementing the community stakeholder engagement model, the mid-term evaluation process, and the outcomes of the mid-term evaluation
Community mapping: a two-day community mapping was conducted as an entry point into the community with 65 stakeholders engaged with HIV response in Jos metropolis. These were journalists, research team members, representatives of Community Based Organisations (CBO) working in Jos Metropolis, policy makers from the Plateau State Ministry of Health and the Plateau State Agency for the Control of AIDS, Plateau State Chapters of the Network of People Living with HIV, the Network of Youths living with HIV and the Network of Civil Society working on HIV and AIDS, representatives of the Plateau State Metropolitan Development Board, State Association of Nurses and Midwives, Association of Hospital and Administrative Pharmacists, representatives of support groups for people living with HIV and AIDS in Plateau State, non-governmental organisations, youth, women traditional leaders, Islamic and Christian religious groups
Summary
The field of HIV vaccine development was reinvigorated by the results of the ALVAC-HIV (vCP1521) (Sanofi Pasteur)/AIDSVAX B/E (Global Solutions for Infectious Diseases) trial that demonstrated 31.2% protection [1], and lower risk of HIV infection for the study population when compared with populations in other trials [2,3,4,5,6]. Community and stakeholder engagement was prioritised for this project because it was considered an ethical imperative [14,15] as it enhances the quality and outcome of research [15,16], facilitates social change emanating from individual and community empowerment in support of health and development [17] and enhances the science, the sense of joint ownership of a study by both researchers and research stakeholder [17] In effect, it improves research implementation, procedures, and outcomes; and helps to build effective and sustainable research collaborations [18]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
